Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques

Cardiovascular Research

Volumn 109, Issue 2, 2016, Pages 283-293

  Lewis, Daniel R ^a,b   Petersen, Latrisha K ^b   York, Adam W ^b   Ahuja, Sonali ^b   Chae, Hoonbyung ^b   Joseph, Laurie B ^c   Rahimi, Saum ^d   Uhrich, Kathryn E ^c   Haser, Paul B ^d   Moghe, Prabhas V ^a,b  

^a The State University of New Jersey   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Alpha Tocopherol; Atherosclerosis; Inflammation; Macrophages; Nanotechnology

Indexed keywords

ALPHA TOCOPHEROL; AMPHOPHILE; BIOLOGICAL MARKER; MACROGOL; NANOPARTICLE; POLYMER; SCAVENGER RECEPTOR; LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BIOACCUMULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; EX VIVO STUDY; FOAM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; INTRACELLULAR SIGNALING; LIPID TRANSPORT; MACROMOLECULE; MACROPHAGE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; THERANOSTIC NANOMEDICINE; DRUG EFFECTS; INFLAMMATION; LIPID METABOLISM; METABOLISM; PLAQUE, ATHEROSCLEROTIC;

FOAM CELLS; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPOPROTEINS, LDL; MACROPHAGES; NANOPARTICLES; PLAQUE, ATHEROSCLEROTIC;

EID: 84959901286     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv237     Document Type: Article

References (54)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Executive Summary: Heart Disease and Stroke Statistics-2010 Update: A report from the American Heart Association. Circulation 2010;121:948-954.
2. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996;20:707-727.
3. Boullier A, Bird DA, Chang M-K, Dennis EA, Friedman P, Gillotte-Taylor K, Hörkkö S, PalinskiW, Quehenberger O, Shaw P, Steinberg D, Terpstra V, Witztum JL. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann NY Acad Sci 2001;947:214-223.
4. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999;340:115-126.
5. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998;101:353-363.
6. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-281.
7. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000;105:1049-1056.
8. Whitman SC, Rateri DL, Szilvassy SJ, Cornicelli JA, Daugherty A. Macrophage-specific expression of class A scavenger receptors in LDL receptor(-/-) mice decreases atherosclerosis and changes spleen morphology. J Lipid Res 2002;43:1201-1208.
9. van Tits LJH, Stienstra R, van Lent PL, Netea MG, Joosten LAB, Stalenhoef AFH. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: A crucial role for Krüppel-like factor 2. Atherosclerosis 2011;214:345-349.
10. Robbesyn F, Salvayre R, Negre-Salvayre A. Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic Res 2004;38:541-551.
11. Gotto AM. Antioxidants, statins, and atherosclerosis. J Am Coll Cardiol 2003;41: 1205-1210.
12. Niki E. Antioxidants and atherosclerosis. Biochem Soc Trans 2004;32:156-159.
13. Saremi A, Arora R. Vitamin E and cardiovascular disease. Am J Ther 2010;17:e56-e65.
14. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis?: Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002;105:2107-2111.
15. Kissner R, Nauser T, Bugnon P, Lye PG, Koppenol WH. Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem Res Toxicol 1997;10:1285-1292.
16. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci 2009;106:9815-9819.
17. Lewis DR, Kamisoglu K, York AW, Moghe PV. Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011;3:400-420.
18. Chnari E, Nikitczuk JS, Wang J, Uhrich KE, Moghe PV. Engineered polymeric nanoparticles for receptor-Targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages. Biomacromolecules 2006;7:1796-1805.
19. Plourde NM, Kortagere S, WelshW, Moghe PV. Structure2activity relations of nanolipoblockers with the atherogenic domain of human macrophage scavenger receptor A. Biomacromolecules 2009;10:1381-1391.
20. Hehir S, Plourde NM, Gu L, Poree DE, Welsh WJ, Moghe PV, Uhrich KE. Carbohydrate composition of amphiphilic macromolecules influences physicochemical properties and binding to atherogenic scavenger receptor A. Acta Biomater 2012;8:3956-3962.
21. Lewis DR, Kholodovych V, Tomasini MD, Abdelhamid D, Petersen LK, Welsh WJ, Uhrich KE, Moghe PV. In silico design of anti-Atherogenic biomaterials. Biomaterials 2013;34:7950-7959.
22. IversonNM, Sparks SM, Demirdirek B, Uhrich KE, Moghe PV. Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers. Acta Biomater 2010;6:3081-3091.
23. York AW, Zablocki KR, Lewis DR, Gu L, Uhrich KE, Prudhomme RK, Moghe PV. Kinetically assembled nanoparticles of bioactive macromolecules exhibit enhanced stability and cell-Targeted biological efficacy. Adv Mater 2012;24:733-739.
24. Johnson BK, Prudhomme RK. Flash nanoprecipitation of organic actives and block copolymers using a confined impinging jets mixer. Aust J Chem 2003;56:1021-1024.
25. Kumar V, Wang L, Riebe M, Tung H-H, Prudhomme RK. Formulation and stability of itraconazole and odanacatib nanoparticles: governing physical parameters. Mol Pharm 2009;6:1118-1124.
26. Gindy ME, Panagiotopoulos AZ, Prudhomme RK. Composite block copolymer stabilized nanoparticles: simultaneous encapsulation of organic actives and inorganic nanostructures. Langmuir 2007;24:83-90.
27. Petersen LK, York AW, Lewis DR, Ahuja S, Uhrich KE, Prudhomme RK, Moghe PV. Amphiphilic nanoparticles repress macrophage atherogenesis: novel core/shell designs for scavenger receptor targeting and down-regulation. Mol Pharm 2014;11:2815-2824.
28. Lewis DR, Petersen LK, York AW, Zablocki KR, Joseph LB, Kholodovych V, Prudhomme RK, Uhrich KE, Moghe PV. Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo. Proc Natl Acad Sci 2015;112:2693-2698.
29. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol 2015;12:10-17.
30. Esterbauer H, Dieber-Rotheneder M, Striegl G, Waeg G. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 1991;53:314S-321S.
31. Beharka AA, Wu D, Serafini M, Meydani SN. Mechanism of vitamin E inhibition of cyclooxygenase activity in macrophages from old mice: role of peroxynitrite. Free Radic Biol Med 2002;32:503-511.
32. Koga T, Kwan P, Zubik L, Ameho C, Smith D, Meydani M. Vitamin E supplementation suppresses macrophage accumulation and endothelial cell expression of adhesion molecules in the aorta of hypercholesterolemic rabbits. Atherosclerosis 2004;176: 265-272.
33. Tian L, Yam L, Zhou N, Tat H, Uhrich KE. Amphiphilic scorpion-like macromolecules:-design, synthesis, and characterization. Macromolecules 2004;37:538-543.
34. Liu Y, Cheng C, Liu Y, Prudhomme RK, Fox RO. Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation. Chem Eng Sci 2008;63:2829-2842.
35. Tomasini MD, Zablocki K, Petersen LK, Moghe PV, Tomassone MS. Coarse grained molecular dynamics of engineered macromolecules for the inhibition of oxidized lowdensity lipoprotein uptake by macrophage scavenger receptors. Biomacromolecules 2013;14:2499-2509.
36. Iverson N, Plourde N, Chnari E, Nackman GB, Moghe PV. Convergence of nanotechnology and cardiovascular medicine. Biodrugs 2008;22:1-10.
37. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: A question of balance. Arterioscler Thromb Vasc Biol 2009;29:1419-1423.
38. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007;37:14-16.
39. Saha P, Modarai B, Humphries J, Mattock K, Waltham M, Burnand KG, Smith A. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr Opin Pharmacol 2009;9:109-118.
40. Clift MJD, Rothen-Rutishauser B, Brown DM, Duffin R, Donaldson K, Proudfoot L, Guy K, Stone V. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol 2008;232: 418-427.
41. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nat Biotechnol 2007;25:1165-1170.
42. Brown DM, Wilson MR, MacNeeW, Stone V, Donaldson K. Size-dependent proinflammatory effects of ultrafine polystyrene particles: A role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol 2001;175:191-199.
43. Stevenson R, Hueber AJ, Hutton A, McInnes IB, Graham D. Nanoparticles and Inflammation. Sci World J 2011;11:1300-1312.
44. Metz S, Bonaterra G, Rudelius M, Settles M, Rummeny E, Daldrup-Link H. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004;14:1851-1858.
45. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008;117:379-387.
46. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-581.
47. Monteiro-Riviere NA, Tran CL. Nanotoxicology: Characterization, Dosing and Health Effects. New York: Informa Healthcare; 2007.
48. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005;3:63-68.
49. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008;172: 1112-1126.
50. Traber MG, Kayden HJ. Vitamin E is delivered to cells via the high affinity receptor for low-density lipoprotein. Am J Clin Nutr 1984;40:747-751.
51. Chinetti-Gbaguidi G, Staels B. Macrophage polarization in metabolic disorders: functions and regulation. Curr Opin Lipidol 2011;22:365-372.
52. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston A-T, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010;5:e8852.
53. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3: 23-35.
54. Auge N, Garcia V, Maupas-Schwalm F, Levade T, Salvayre R, Negre-Salvayre A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol 2002;22:1990-1995.